Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
about
Linezolid versus vancomycin for skin and soft tissue infectionsLinezolid versus vancomycin for skin and soft tissue infectionsLinezolid versus vancomycin for skin and soft tissue infectionsBench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumoniaMethicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of ChinaTreatment of Gram-positive infections in critically ill patientsLinezolid has unique immunomodulatory effects in post-influenza community acquired MRSA pneumoniaDiagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay.The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis.Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis.Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia.Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP studyLinezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.Linezolid versus vancomycin for skin and soft tissue infections.Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis.Feeding, simvastatin, and linezolidDifferences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: a comparison of the EUVAP and LATINVAP study cohorts.Response to emerging infection leading to outbreak of linezolid-resistant enterococci.Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency MedicineRecombinant lysostaphin protects mice from methicillin-resistant Staphylococcus aureus pneumoniaComparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus.Capsaicin protects mice from community-associated methicillin-resistant Staphylococcus aureus pneumoniaCommunity-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia without evidence of antecedent viral upper respiratory infection.An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Vascular catheter-associated infections: a microbiological and therapeutic update.Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfectionThe efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infectionsTelavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.Current and novel antibiotics against resistant Gram-positive bacteriaLEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant.In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococciColonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms.Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).
P2860
Q24186563-544B3DCF-EC0F-4D92-8E86-529A52227CD6Q24201228-6C9EAADF-0FC6-4A36-A66B-119884415F08Q24240912-DE19309B-45DC-4AF0-B88A-B56C5F8FEE32Q24811492-A54A9783-D698-4207-9AFE-55AD59BF4F8EQ26749179-066B782F-43F5-43AF-8FDD-F65FD6BFAE68Q27015976-434FF988-051F-4DEF-9C73-7A146AE463C9Q28543159-A89C9EF2-FB25-4421-BBB5-DEE828AF9281Q30608976-A4A33C21-B75D-45F2-A52E-35FA86782A59Q33246169-BE72532B-7B13-47F8-B01E-6DC0A25B2A32Q33370027-B75F8D8F-B633-4A21-9605-BFD9274B770BQ33410942-22BC5CA2-9B7B-4343-9888-B75FA14A90EDQ33412202-660092F7-F195-4D94-B333-53F5178387E1Q33415857-7A3D6136-D6AE-4333-8517-B4FBDCB5C042Q33418451-C34424B7-413D-4C0A-8705-9308950D12D9Q33418740-CBD4F834-DA44-45B5-A2D1-B275524346A9Q33716771-1FCF0ED0-4AE5-4920-8F13-55BF25B15F62Q33738977-1DCFB872-7E13-4CD2-A36C-EA3B99C5D928Q33790761-C151DFFB-CB4E-48EB-9175-7DE600437857Q33884094-6B355FF6-0F81-4125-8434-F631FC0C87EDQ33974292-A754EB84-FFC1-402A-99A9-1FE904A93679Q34012319-FA2FFB9C-60BC-4197-B2BE-B9D02DE5859FQ34150985-3D48FE4E-553D-4402-A8F4-AAE6248E0918Q34200320-D542C19D-E7CA-4575-890B-B30B0E653E59Q34238568-8CC59A15-7F55-45CA-AF00-85B6B9F11DB0Q34434763-E2181D42-7429-4A95-B5C9-14B76950AA4DQ34452009-00A6B8E0-85AC-4B96-91CA-1572910E309BQ34470298-EB88A173-19E0-4A9C-8F27-63610D6AEC40Q34478074-1905D6A5-BE14-455A-973E-9619A40D9BF2Q34585059-7822423E-C823-48AA-BACE-1BB1B869EE7DQ34616215-BDE52A48-A808-48BC-B15E-2A158A616869Q34618696-775D878D-253B-4873-9451-A7426AC4FDB5Q34699108-8F6CEFC3-8306-418A-9DED-A3215EB81404Q34923394-ADC1F849-FC69-48BE-8D5A-F5E5C79A6B73Q35026521-3BDA36B1-6532-4EED-8AEB-463F68ECDA95Q35139437-CC5FFFB5-2E98-430F-85B0-28C71B103553Q35139518-4B2756B3-6936-4A53-8847-6408EAD78C7FQ35647735-EA86C72D-3395-4A56-967E-0480C7CD0BC0Q35736907-94077285-0F77-4491-85D7-A419524483E3Q35873712-21FA2F9E-0AC7-40F4-9ADF-D8C220FB3910Q35905561-55AD5C65-74E7-4FD2-ABE1-C310F94C1B28
P2860
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Linezolid vs vancomycin: analy ...... s aureus nosocomial pneumonia.
@en
Linezolid vs vancomycin: analy ...... s aureus nosocomial pneumonia.
@nl
type
label
Linezolid vs vancomycin: analy ...... s aureus nosocomial pneumonia.
@en
Linezolid vs vancomycin: analy ...... s aureus nosocomial pneumonia.
@nl
prefLabel
Linezolid vs vancomycin: analy ...... s aureus nosocomial pneumonia.
@en
Linezolid vs vancomycin: analy ...... s aureus nosocomial pneumonia.
@nl
P50
P921
P1433
P1476
Linezolid vs vancomycin: analy ...... s aureus nosocomial pneumonia.
@en
P2093
Richard G Wunderink
Rodney V Croos-Dabrera
P304
P356
10.1016/S0012-3692(15)33412-7
P407
P577
2003-11-01T00:00:00Z